USFDA completes inspection of Lupin’s Aurangabad unit
DSIJ Intelligence / 31 Jul 2017
In a BSE filing on Monday, Pharma major Lupin, announced the completion of a PAI inspection (Prior Approval Inspection) carried out by the USFDA of its Aurangabad manufacturing facility with one 483 observation.
In a BSE filing on Monday, Pharma major Lupin, announced the completion of a PAI inspection (Prior Approval Inspection) carried out by the USFDA of its Aurangabad manufacturing facility with one 483 observation.
The company also said that the observation was procedural in nature and corrected during the inspection itself.
At Rs 1,045.35 per share, Lupin was trading down by Rs 17.50 or 1.65% as at 1352 hours on Monday, on the BSE. The stock witnessed a spurt in volume by more than 2.56 times and hit its intraday high and low of Rs 1,090 and Rs 1,037.50, respectively.
The stock attracted a traded value of Rs 34,176.14 lakh and a traded volume of 32,61,393 shares on the NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.